Corgenix to Launch New Hepcidin-25 Product at the American Society of Hematology Annual Meeting

06 Dec 2013
Share
Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, announced today that it will launch the Research-Use-Only (RUO) Hepcidin-25 Chemiluminescent Direct ELISA test kit at the 55th Annual Meeting of the American Society of Hematology (ASH®) at the Ernest N. Morial Convention Center in New Orleans. The test kit is based on technology originally developed at Eli Lilly and Company and licensed for further development by Corgenix.

“The ASH annual meeting is the ideal strategic launching pad for important new products related to anemia and cancer; therefore, it is a natural choice for us to launch the new Hepcidin-25 RUO product at this prestigious event,” said Douglass Simpson, President and CEO of Corgenix. “We are very pleased to be able to introduce this high quality test kit to the global research community, opening a new door for Corgenix.”

Hepcidin, a hepatic peptide hormone, is a key regulator of iron metabolism. Hepcidin deficiency has been linked to hemochromatosis and iron overload, whereas increased concentrations have been reported in anemia of cancer and other chronic diseases. The new technology enables the measurement of serum concentrations of hepcidin-25, the active form of the hormone.

To learn more about the Hepcidin-25 Chemiluminescent Direct ELISA test kit, please visit the Company's booth # 3921 at the ASH meeting, December 7-10, 2013. The Hepcidin-25 Chemiluminescent Direct ELISA test kit has not been cleared or approved by the U.S. Food and Drug Administration for diagnostic purposes.

Request Info


Company website

Corgenix
profile photo

Sonia Nicholas
Clinical Diagnostics Editor